for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

DelMar Pharmaceuticals Inc

DMPI.OQ

Latest Trade

0.81USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

0.38

 - 

2.65

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Delmar Pharmaceuticals Reports Q3 Loss Per Share $0.17

May 13 (Reuters) - DelMar Pharmaceuticals Inc <DMPI.O>::DELMAR PHARMACEUTICALS ANNOUNCES FISCAL THIRD QUARTER 2020 FINANCIAL RESULTS AND RECENT CORPORATE UPDATES.Q3 LOSS PER SHARE $0.17.AT MARCH 31, 2020, COMPANY HAD CASH AND CASH EQUIVALENTS OF APPROXIMATELY $5.0 MILLION.DELMAR PHARMA- CASH,CASH EQUIVALENTS AT MARCH 31, 2020 ARE EXPECTED TO BE SUFFICIENT TO FUND CO'S PLANNED OPERATIONS INTO Q4 OF CALENDAR YEAR 2020.

DelMar Pharmaceuticals Provides Enrollment Update In Phase 2 Clinical Trial Of Val-083 For Adjuvant Treatment Of Brain Tumors

May 5 (Reuters) - DelMar Pharmaceuticals Inc <DMPI.O>::DELMAR PHARMACEUTICALS [NASDAQ:DMPI] PROVIDES ENROLLMENT UPDATE IN PHASE 2 CLINICAL TRIAL OF VAL-083 FOR ADJUVANT TREATMENT OF BRAIN TUMORS.DELMAR PHARMACEUTICALS INC - PHASE 2 TRIAL MORE THAN 90% ENROLLED WITH ENROLLMENT CONTINUING EVEN IN LIGHT OF CORONAVIRUS PANDEMIC.DELMAR PHARMACEUTICALS - ENROLLED 22 PATIENTS IN ADJUVANT ARM OF CO'S PHASE 2 CLINICAL STUDY INVESTIGATING ADJUVANT TREATMENT OF GBM WITH VAL-083.

Delmar Pharma Has Until Dec 7 To Regain Compliance With Nasdaq

April 21 (Reuters) - DelMar Pharmaceuticals Inc <DMPI.O>::DELMAR PHARMACEUTICALS - HAS UNTIL DECEMBER 7, 2020 TO REGAIN COMPLIANCE WITH NASDAQ.

Delmar Pharma Enrolls Final Patient In Phase 2 Clinical Trial Of Val-083 For First-Line Treatment Of Brain Tumors

Feb 19 (Reuters) - DelMar Pharmaceuticals Inc <DMPI.O>::DELMAR PHARMACEUTICALS [NASDAQ:DMPI] ENROLLS FINAL PATIENT IN PHASE 2 CLINICAL TRIAL OF VAL-083 FOR FIRST-LINE TREATMENT OF BRAIN TUMORS.DELMAR PHARMACEUTICALS INC - ANTICIPATES EARLIER THAN EXPECTED PRELIMINARY DATA READOUT IN AUGUST 2020.DELMAR PHARMACEUTICALS INC - HAS BEEN MONITORING CORONAVIRUS SITUATION IN CHINA.DELMAR PHARMACEUTICALS - CORONAVIRUS OUTBREAK WILL NOT HAVE SIGNIFICANT IMPACT ON PATIENT TREATMENT TIMELINE.

Delmar Pharmaceuticals Q2 Loss Per Share $0.15

Feb 13 (Reuters) - DelMar Pharmaceuticals Inc <DMPI.O>::DELMAR PHARMACEUTICALS ANNOUNCES FISCAL SECOND QUARTER 2020 FINANCIAL RESULTS AND RECENT CORPORATE UPDATES.Q2 LOSS PER SHARE $0.15.

Delmar Pharma Says Offering 7.8 Mln Shares Of Common Stock Issuable Upon Exercise Of Previously Issued Warrants

Nov 21 (Reuters) - DelMar Pharmaceuticals Inc <DMPI.O>::DELMAR PHARMACEUTICALS INC - OFFERING 7.8 MILLION SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF PREVIOUSLY ISSUED WARRANTS -SEC FILING.

Delmar Pharmaceuticals Q1 Loss Per Share $0.21

Nov 14 (Reuters) - DelMar Pharmaceuticals Inc <DMPI.O>::DELMAR PHARMACEUTICALS ANNOUNCES FISCAL FIRST QUARTER 2020 FINANCIAL RESULTS AND RECENT CORPORATE UPDATES.Q1 LOSS PER SHARE $0.21.DELMAR PHARMACEUTICALS - AT SEPT 30, CO HAD CASH AND CASH EQUIVALENTS ON HAND OF ABOUT $8.1 MILLION.

DelMar Says During Audit For Year-Ended June 30, 2019, Material Weakness In Operating Effectiveness Of Internal Controls Over Financial Reporting Was Identified

Oct 1 (Reuters) - DelMar Pharmaceuticals Inc <DMPI.O>::DELMAR- DURING AUDIT FOR YEAR-ENDED JUNE 30, 2019, MATERIAL WEAKNESS IN OPERATING EFFECTIVENESS OF INTERNAL CONTROLS OVER FINANCIAL REPORTING WAS IDENTIFIED.DELMAR - WEAKNESS RELATED TO INADEQUATE SEGREGATION OF DUTIES OVER AUTHORIZATION, REVIEW & RECORDING OF TRANSACTIONS, AS WELL AS FINANCIAL REPORTING.DELMAR PHARMACEUTICALS INC - ON SEPT. 30, E&Y RESIGNED AS CO'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM..

DelMar Pharmaceuticals Files For Offering 6 Mln Shares Of Common Stock

Aug 1 (Reuters) - DelMar Pharmaceuticals Inc <DMPI.O>::DELMAR PHARMACEUTICALS INC FILES FOR OFFERING 6 MILLION SHARES OF COMMON STOCK, WARRANTS TO PURCHASE SHARES OF COMMON STOCK - SEC FILING.

DelMar Pharmaceuticals Enrolls First Patient In The Recently-Approved Adjuvant Setting Arm Of Phase 2 Study Of VAL-083

July 24 (Reuters) - DelMar Pharmaceuticals Inc <DMPI.O>::DELMAR PHARMACEUTICALS ENROLLS FIRST PATIENT IN THE RECENTLY-APPROVED ADJUVANT SETTING ARM OF PHASE 2 STUDY OF VAL-083 FOR THE TREATMENT OF MGMT-UNMETHYLATED GLIOBLASTOMA MULTIFORME.DELMAR PHARMACEUTICALS INC - DELMAR IS ACTIVELY ENROLLING PATIENTS FOR BOTH TRIAL ARMS OF CLINICAL STUDY AT MDACC..DELMAR PHARMACEUTICALS INC - CONDUCTING A PHASE 2 CLINICAL STUDY OF VAL-083 AS FIRST LINE TREATMENT FOR GBM IN COMBINATION WITH RADIOTHERAPY IN CHINA.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up